Basic Information
RNALocate ID: | RLID:11000692 |
RNA Symbol: | hsa-miR-17-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-17-5p |
RNA ID: | miRBase:MIMAT0000070 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001267 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001268 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001269 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001270 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001271 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001272 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001273 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001274 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001275 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001276 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11000686 | Exosome | Serum | 29143228 |
RLID:11000687 | Exosome | Peripheral blood mononuclear cells | 19002258 |
RLID:11000688 | Exosome | Saliva | 19627513 |
RLID:11000689 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000690 | Exosome | Breast milk | 22211110 |
RLID:11000691 | Exosome | Brain tissue | 23382797 |
RLID:11000693 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000694 | Exosome | Cerebrospinal fluid | 25420022 |
RLID:11000695 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11000696 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000697 | Microvesicle | Follicular fluid | 23666971 |
RLID-D:11000009 | Exosome | B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Colon tissue|Endothelial cells|Epithelial cells|Lymphoma tissue|Mast cells|Tongue tissue | |
RLID-D:11000269 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-17-5p | Diffuse large b cell lymphoma | MNDR-E-MI-19078 |
MNDR | hsa-miR-17-5p | Splenic marginal zone lymphoma | MNDR-E-MI-19079 |
MNDR | hsa-miR-17-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-19080 |
MNDR | hsa-miR-17-5p | Oral squamous cell carcinoma | MNDR-E-MI-19081 |
MNDR | hsa-miR-17-5p | Large cell neuroendocrine cancer | MNDR-E-MI-19082 |
MNDR | hsa-miR-17-5p | Follicular cleaved lymphoma | MNDR-E-MI-19083 |
MNDR | hsa-miR-17-5p | Medulloblastoma | MNDR-E-MI-19084 |
MNDR | hsa-miR-17-5p | B cell lymphoma of malt type | MNDR-E-MI-19085 |
MNDR | hsa-miR-17-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-19086 |
MNDR | hsa-miR-17-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-19087 |
MNDR | hsa-miR-17-5p | Ovarian clear cell carcinoma | MNDR-E-MI-19088 |
MNDR | hsa-miR-17-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-19089 |
MNDR | hsa-miR-17-5p | Autism spectrum disorder | MNDR-E-MI-19090 |
MNDR | hsa-miR-17-5p | Lymphoma | MNDR-E-MI-19091 |
MNDR | hsa-miR-17-5p | Lymphoma non-hodgkin | MNDR-E-MI-19092 |
MNDR | hsa-miR-17-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-19093 |
MNDR | hsa-miR-17-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-19094 |
MNDR | hsa-miR-17-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-19095 |
MNDR | hsa-miR-17-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-19096 |
MNDR | hsa-miR-17-5p | Her2-receptor positive breast cancer | MNDR-E-MI-19097 |
MNDR | hsa-miR-17-5p | Breast cancer luminal | MNDR-E-MI-19098 |
MNDR | hsa-miR-17-5p | Lymphoblastic lymphoma | MNDR-E-MI-19099 |
MNDR | hsa-miR-17-5p | Polycystic kidney diseases | MNDR-E-MI-19100 |
MNDR | hsa-miR-17-5p | Thyroid carcinoma anaplastic | MNDR-E-MI-19101 |
MNDR | hsa-miR-17-5p | Small intestine cancer | MNDR-E-MI-19102 |
MNDR | hsa-miR-17-5p | Dermatomyositis | MNDR-E-MI-19103 |
MNDR | hsa-miR-17-5p | Prostate cancer | MNDR-E-MI-19104 |
MNDR | hsa-miR-17-5p | Gastric cancer | MNDR-E-MI-19105 |
MNDR | hsa-miR-17-5p | Gastric lymphoma | MNDR-E-MI-19106 |
MNDR | hsa-miR-17-5p | Alzheimer disease | MNDR-E-MI-19107 |
MNDR | hsa-miR-17-5p | Intracranial aneurysm | MNDR-E-MI-19108 |
MNDR | hsa-miR-17-5p | Bladder cancer | MNDR-E-MI-19109 |
MNDR | hsa-miR-17-5p | Esophageal carcinoma | MNDR-E-MI-19110 |
MNDR | hsa-miR-17-5p | Sarcoma | MNDR-E-MI-19111 |
MNDR | hsa-miR-17-5p | Dysautonomia familial | MNDR-E-MI-19112 |
MNDR | hsa-miR-17-5p | Primary biliary cirrhosis | MNDR-E-MI-19113 |
MNDR | hsa-miR-17-5p | Leukemia | MNDR-E-MI-19114 |
MNDR | hsa-miR-17-5p | Huntington disease | MNDR-E-MI-19115 |
MNDR | hsa-miR-17-5p | Chorea | MNDR-E-MI-19116 |
MNDR | hsa-miR-17-5p | Cardiovascular disease | MNDR-E-MI-19117 |
MNDR | hsa-miR-17-5p | Carotid stenosis | MNDR-E-MI-19118 |
MNDR | hsa-miR-17-5p | Lung cancer | MNDR-E-MI-19119 |
MNDR | hsa-miR-17-5p | Down syndrome | MNDR-E-MI-19120 |
MNDR | hsa-miR-17-5p | Parkinson disease | MNDR-E-MI-19121 |
MNDR | hsa-miR-17-5p | Basal-like breast cancer | MNDR-E-MI-19122 |
MNDR | hsa-miR-17-5p | Thyroid cancer | MNDR-E-MI-19123 |
MNDR | hsa-miR-17-5p | Pituitary neoplasms | MNDR-E-MI-19124 |
MNDR | hsa-miR-17-5p | Pancreatic cancer | MNDR-E-MI-19125 |
MNDR | hsa-miR-17-5p | Malignant melanoma | MNDR-E-MI-19126 |
MNDR | hsa-miR-17-5p | Lesch-nyhan syndrome | MNDR-E-MI-19127 |
MNDR | hsa-miR-17-5p | Rectum adenocarcinoma | MNDR-E-MI-19128 |
MNDR | hsa-miR-17-5p | Nephroblastoma | MNDR-E-MI-19129 |
MNDR | hsa-miR-17-5p | Colon cancer | MNDR-E-MI-19130 |
MNDR | hsa-miR-17-5p | Ischemic attack transient | MNDR-E-MI-19131 |
MNDR | hsa-miR-17-5p | Colon adenocarcinoma | MNDR-E-MI-19132 |
MNDR | hsa-miR-17-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-19133 |
MNDR | hsa-miR-17-5p | Familial ovarian cancer | MNDR-E-MI-19134 |
MNDR | hsa-miR-17-5p | Acromegaly | MNDR-E-MI-19135 |
MNDR | hsa-miR-17-5p | Prostate adenocarcinoma | MNDR-E-MI-19136 |
MNDR | hsa-miR-17-5p | Kidney cancer | MNDR-E-MI-19137 |
MNDR | hsa-miR-17-5p | Carcinoma ductal breast | MNDR-E-MI-19138 |
MNDR | hsa-miR-17-5p | Invasive ductal carcinoma | MNDR-E-MI-19139 |
MNDR | hsa-miR-17-5p | Glioblastoma | MNDR-E-MI-19140 |
MNDR | hsa-miR-17-5p | Glioma | MNDR-E-MI-19141 |
MNDR | hsa-miR-17-5p | Oligodendroglioma | MNDR-E-MI-19142 |
MNDR | hsa-miR-17-5p | Central nervous system lymphoma | MNDR-E-MI-19143 |
MNDR | hsa-miR-17-5p | Chordoma | MNDR-E-MI-19144 |
MNDR | hsa-miR-17-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-19145 |
MNDR | hsa-miR-17-5p | Epilepsy temporal lobe | MNDR-E-MI-19146 |
MNDR | hsa-miR-17-5p | Osteosarcoma | MNDR-E-MI-19147 |
MNDR | hsa-miR-17-5p | Liposarcoma | MNDR-E-MI-19148 |
MNDR | hsa-miR-17-5p | Coronary artery disease | MNDR-E-MI-19149 |
MNDR | hsa-miR-17-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-19150 |
MNDR | hsa-miR-17-5p | Middle cerebral artery infarction | MNDR-E-MI-19151 |
MNDR | hsa-miR-17-5p | Meningioma | MNDR-E-MI-19152 |
MNDR | hsa-miR-17-5p | Liver cancer | MNDR-E-MI-19153 |
MNDR | hsa-miR-17-5p | Gastric adenocarcinoma | MNDR-E-MI-19154 |
MNDR | hsa-miR-17-5p | Cervical squamous cell carcinoma | MNDR-E-MI-19155 |
MNDR | hsa-miR-17-5p | Pituitary adenoma | MNDR-E-MI-19156 |
MNDR | hsa-miR-17-5p | Lung squamous cell carcinoma | MNDR-E-MI-19157 |
MNDR | hsa-miR-17-5p | Carcinoma lung non-small-cell | MNDR-E-MI-19158 |
MNDR | hsa-miR-17-5p | Lung adenocarcinoma | MNDR-E-MI-19159 |
MNDR | hsa-miR-17-5p | Adrenocortical carcinoma | MNDR-E-MI-19160 |
MNDR | hsa-miR-17-5p | Thyroid carcinoma | MNDR-E-MI-19161 |
MNDR | hsa-miR-17-5p | Ovarian carcinoma | MNDR-E-MI-19162 |
MNDR | hsa-miR-17-5p | Bladder urothelial carcinoma | MNDR-E-MI-19163 |
MNDR | hsa-miR-17-5p | Pancreatic adenocarcinoma | MNDR-E-MI-19164 |
MNDR | hsa-miR-17-5p | Cervical cancer | MNDR-E-MI-19165 |
MNDR | hsa-miR-17-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-19166 |
MNDR | hsa-miR-17-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-19167 |
MNDR | hsa-miR-17-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-19168 |
MNDR | hsa-miR-17-5p | Clear cell renal cell carcinoma | MNDR-E-MI-19169 |
MNDR | hsa-miR-17-5p | Biliary tract cancer | MNDR-E-MI-19170 |
MNDR | hsa-miR-17-5p | Pituitary carcinoma | MNDR-E-MI-19171 |
MNDR | hsa-miR-17-5p | Cholangiocarcinoma | MNDR-E-MI-19172 |
MNDR | hsa-miR-17-5p | Esophageal cancer | MNDR-E-MI-19173 |
MNDR | hsa-miR-17-5p | Liver cirrhosis | MNDR-E-MI-19174 |
MNDR | hsa-miR-17-5p | Prolactinoma | MNDR-E-MI-19175 |
MNDR | hsa-miR-17-5p | Lung small cell carcinoma | MNDR-E-MI-19176 |
MNDR | hsa-miR-17-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-19177 |
MNDR | hsa-miR-17-5p | Kidney diseases | MNDR-E-MI-19178 |
MNDR | hsa-miR-17-5p | T acute lymphoblastic leukemia | MNDR-E-MI-19179 |
MNDR | hsa-miR-17-5p | Acute t cell leukemia | MNDR-E-MI-19180 |
MNDR | hsa-miR-17-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-19181 |
MNDR | hsa-miR-17-5p | Fibromyalgia | MNDR-E-MI-19182 |
MNDR | hsa-miR-17-5p | Pulmonary hypertension | MNDR-E-MI-19183 |
MNDR | hsa-miR-17-5p | Adenoma | MNDR-E-MI-19184 |
MNDR | hsa-miR-17-5p | Breast invasive carcinoma | MNDR-E-MI-19185 |
MNDR | hsa-miR-17-5p | Hepatocellular carcinoma | MNDR-E-MI-19186 |
MNDR | hsa-miR-17-5p | Familiar ovarian carcinoma | MNDR-E-MI-19187 |
MNDR | hsa-miR-17-5p | B-cell lymphoma | MNDR-E-MI-19188 |
MNDR | hsa-miR-17-5p | Rheumatoid arthritis | MNDR-E-MI-19189 |
MNDR | hsa-miR-17-5p | T-cell leukemia | MNDR-E-MI-19190 |
MNDR | hsa-miR-17-5p | Retinoblastoma | MNDR-E-MI-19191 |
MNDR | hsa-miR-17-5p | Neuroblastoma | MNDR-E-MI-19192 |
MNDR | hsa-miR-17-5p | Chronic fatigue syndrome | MNDR-E-MI-19193 |
MNDR | hsa-miR-17-5p | Chronic myeloid leukemia | MNDR-E-MI-19194 |
MNDR | hsa-miR-17-5p | Hodgkin lymphoma | MNDR-E-MI-19195 |
MNDR | hsa-miR-17-5p | Burkitt lymphoma | MNDR-E-MI-19196 |
MNDR | hsa-miR-17-5p | Lymphosarcoma | MNDR-E-MI-19197 |
MNDR | hsa-miR-17-5p | Tonsil cancer | MNDR-E-MI-19198 |
MNDR | hsa-miR-17-5p | Psoriasis | MNDR-E-MI-19199 |
MNDR | hsa-miR-17-5p | Acute myelocytic leukemia | MNDR-E-MI-19200 |
MNDR | hsa-miR-17-5p | Colorectal cancer | MNDR-E-MI-19201 |
MNDR | hsa-miR-17-5p | Nasopharyngeal carcinoma | MNDR-E-MI-19202 |
MNDR | hsa-miR-17-5p | Type 2 diabetes mellitus | MNDR-E-MI-19203 |
MNDR | hsa-miR-17-5p | Multiple myeloma | MNDR-E-MI-19204 |
MNDR | hsa-miR-17-5p | Uterine cervical neoplasms | MNDR-E-MI-19205 |
MNDR | hsa-miR-17-5p | Ependymoma | MNDR-E-MI-19206 |
MNDR | hsa-miR-17-5p | Nasopharyngeal cancer | MNDR-E-MI-19207 |
MNDR | hsa-miR-17-5p | Prostatic neoplasms | MNDR-E-MI-19208 |
MNDR | hsa-miR-17-5p | Arsenic poisoning | MNDR-E-MI-19209 |
MNDR | hsa-miR-17-5p | Stroke lacunar | MNDR-E-MI-19210 |
MNDR | hsa-miR-17-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-19211 |
MNDR | hsa-miR-17-5p | Breast cancer her3+ negative | MNDR-E-MI-19212 |
MNDR | hsa-miR-17-5p | Duke A | MNDR-E-MI-19213 |
MNDR | hsa-miR-17-5p | Tubulovillous adenoma | MNDR-E-MI-19214 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCA1 | Homo sapiens | RR00022096 |
TOP